<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration - Moja, L - 2014 | Cochrane Library</title> <meta content="Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration - Moja, L - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration - Moja, L - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011230.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration" name="citation_title"/> <meta content="Lorenzo Moja" name="citation_author"/> <meta content="University of Milan ‐ IRCCS Galeazzi Orthopaedic Institute" name="citation_author_institution"/> <meta content="lorenzo.moja@unimi.it" name="citation_author_email"/> <meta content="Ersilia Lucenteforte" name="citation_author"/> <meta content="University of Florence" name="citation_author_institution"/> <meta content="Koren H Kwag" name="citation_author"/> <meta content="IRCCS Galeazzi Orthopaedic Institute" name="citation_author_institution"/> <meta content="Vittorio Bertele" name="citation_author"/> <meta content="IRCCS Mario Negri Institute for Pharmacological Research" name="citation_author_institution"/> <meta content="Annalisa Campomori" name="citation_author"/> <meta content="Hospital Pharmacy, Trento General Hospital, Health Trust of the Autonomous Province of Trento" name="citation_author_institution"/> <meta content="Usha Chakravarthy" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Roberto D'Amico" name="citation_author"/> <meta content="University of Modena and Reggio Emilia" name="citation_author_institution"/> <meta content="Kay Dickersin" name="citation_author"/> <meta content="Johns Hopkins University" name="citation_author_institution"/> <meta content="Laurent Kodjikian" name="citation_author"/> <meta content="Hôpital de la Croix‐Rousse" name="citation_author_institution"/> <meta content="Kristina Lindsley" name="citation_author"/> <meta content="Johns Hopkins Bloomberg School of Public Health" name="citation_author_institution"/> <meta content="Yoon Loke" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Maureen Maguire" name="citation_author"/> <meta content="University of Pennsylvania" name="citation_author_institution"/> <meta content="Daniel F Martin" name="citation_author"/> <meta content="Cleveland Clinic" name="citation_author_institution"/> <meta content="Alessandro Mugelli" name="citation_author"/> <meta content="University of Florence" name="citation_author_institution"/> <meta content="Bernd Mühlbauer" name="citation_author"/> <meta content="Klinikum Bremen Mitte gGmbH" name="citation_author_institution"/> <meta content="Isabel Püntmann" name="citation_author"/> <meta content="Klinikum Bremen Mitte gGmbH" name="citation_author_institution"/> <meta content="Barnaby Reeves" name="citation_author"/> <meta content="University of Bristol" name="citation_author_institution"/> <meta content="Chris Rogers" name="citation_author"/> <meta content="University of Bristol" name="citation_author_institution"/> <meta content="Christine Schmucker" name="citation_author"/> <meta content="Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg" name="citation_author_institution"/> <meta content="Manju L Subramanian" name="citation_author"/> <meta content="Boston University, School of Medicine" name="citation_author_institution"/> <meta content="Gianni Virgili" name="citation_author"/> <meta content="University of Florence" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD011230.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/09/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angiogenesis Inhibitors [administration &amp; dosage, *adverse effects]; Antibodies, Monoclonal, Humanized [administration &amp; dosage, *adverse effects]; Bevacizumab; Intravitreal Injections; Macular Degeneration [*drug therapy, mortality]; Ranibizumab; Vascular Endothelial Growth Factor A [antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011230.pub2&amp;doi=10.1002/14651858.CD011230.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011230\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011230\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011230.pub2",title:"Systemic safety of bevacizumab versus ranibizumab for neovascular age\\u2010related macular degeneration",firstPublishedDate:"Sep 15, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011230.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011230.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011230.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011230.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011230.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011230.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011230.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011230.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011230.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011230.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2880 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011230.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-sec-0067"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-sec-0061"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/table_n/CD011230StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/table_n/CD011230StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lorenzo Moja</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0003">Ersilia Lucenteforte</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0004">Koren H Kwag</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0005">Vittorio Bertele</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0006">Annalisa Campomori</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0007">Usha Chakravarthy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0008">Roberto D'Amico</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0009">Kay Dickersin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0010">Laurent Kodjikian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0011">Kristina Lindsley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0012">Yoon Loke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0013">Maureen Maguire</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0014">Daniel F Martin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0015">Alessandro Mugelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0016">Bernd Mühlbauer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0017">Isabel Püntmann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0018">Barnaby Reeves</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0019">Chris Rogers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0020">Christine Schmucker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0021">Manju L Subramanian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information#CD011230-cr-0022">Gianni Virgili</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information/en#CD011230-sec-0073">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 September 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011230.pub2">https://doi.org/10.1002/14651858.CD011230.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011230-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011230-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011230-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011230-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011230-abs-0001" lang="en"> <section id="CD011230-sec-0001"> <h3 class="title" id="CD011230-sec-0001">Background</h3> <p>Neovascular age‐related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby preventing its pathological angiogenesis. Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevacizumab is approved for intravenous use as a cancer therapy. However, due to the biological similarity of the two drugs, bevacizumab is widely used off‐label to treat neovascular AMD. </p> </section> <section id="CD011230-sec-0002"> <h3 class="title" id="CD011230-sec-0002">Objectives</h3> <p>To assess the systemic safety of intravitreal bevacizumab (brand name Avastin®; Genentech/Roche) compared with intravitreal ranibizumab (brand name Lucentis®; Novartis/Genentech) in people with neovascular AMD. Primary outcomes were death and All serious systemic adverse events (All SSAEs), the latter as a composite outcome in accordance with the International Conference on Harmonisation Good Clinical Practice. Secondary outcomes examined specific SSAEs: fatal and non‐fatal myocardial infarctions, strokes, arteriothrombotic events, serious infections, and events grouped in some Medical Dictionary for Regulatory Activities System Organ Classes (MedDRA SOC). We assessed the safety at the longest available follow‐up to a maximum of two years. </p> </section> <section id="CD011230-sec-0003"> <h3 class="title" id="CD011230-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, EMBASE and other online databases up to 27 March 2014. We also searched abstracts and clinical study presentations at meetings, trial registries, and contacted authors of included studies when we had questions. </p> </section> <section id="CD011230-sec-0004"> <h3 class="title" id="CD011230-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) directly comparing intravitreal bevacizumab (1.25 mg) and ranibizumab (0.5 mg) in people with neovascular AMD, regardless of publication status, drug dose, treatment regimen, or follow‐up length, and whether the SSAEs of interest were reported in the trial report. </p> </section> <section id="CD011230-sec-0005"> <h3 class="title" id="CD011230-sec-0005">Data collection and analysis</h3> <p>Two authors independently selected studies and assessed the risk of bias for each study. Three authors independently extracted data. </p> <p>We conducted random‐effects meta‐analyses for the primary and secondary outcomes. We planned a pre‐specified analysis to explore deaths and All SSAEs at the one‐year follow‐up. </p> </section> <section id="CD011230-sec-0006"> <h3 class="title" id="CD011230-sec-0006">Main results</h3> <p>We included data from nine studies (3665 participants), including six published (2745 participants) and three unpublished (920 participants) RCTs, none supported by industry. Three studies excluded participants at high cardiovascular risk, increasing clinical heterogeneity among studies. The studies were well designed, and we did not downgrade the quality of the evidence for any of the outcomes due to risk of bias. Although the estimated effects of bevacizumab and ranibizumab on our outcomes were similar, we downgraded the quality of the evidence due to imprecision. </p> <p>At the maximum follow‐up (one or two years), the estimated risk ratio (RR) of death with bevacizumab compared with ranibizumab was 1.10 (95% confidence interval (CI) 0.78 to 1.57, P value = 0.59; eight studies, 3338 participants; moderate quality evidence). Based on the event rates in the studies, this gives a risk of death with ranibizumab of 3.4% and with bevacizumab of 3.7% (95% CI 2.7% to 5.3%). </p> <p>For All SSAEs, the estimated RR was 1.08 (95% CI 0.90 to 1.31, P value = 0.41; nine studies, 3665 participants; low quality evidence). Based on the event rates in the studies, this gives a risk of SSAEs of 22.2% with ranibizumab and with bevacizumab of 24% (95% CI 20% to 29.1%). </p> <p>For the secondary outcomes, we could not detect any difference between bevacizumab and ranibizumab, with the exception of gastrointestinal disorders MedDRA SOC where there was a higher risk with bevacizumab (RR 1.82; 95% CI 1.04 to 3.19, P value = 0.04; six studies, 3190 participants). </p> <p>Pre‐specified analyses of deaths and All SSAEs at one‐year follow‐up did not substantially alter the findings of our review. </p> <p>Fixed‐effect analysis for deaths did not substantially alter the findings of our review, but fixed‐effect analysis of All SSAEs showed an increased risk for bevacizumab (RR 1.12; 95% CI 1.00 to 1.26, P value = 0.04; nine studies, 3665 participants): the meta‐analysis was dominated by a single study (weight = 46.9%). </p> <p>The available evidence was sensitive to the exclusion of CATT or unpublished results. For All SSAEs, the exclusion of CATT moved the overall estimate towards no difference (RR 1.01; 95% CI 0.82 to 1.25, P value = 0.92), while the exclusion of LUCAS yielded a larger RR, with more SSAEs in the bevacizumab group, largely driven by CATT (RR 1.19; 95% CI 1.06 to 1.34, P value = 0.004). The exclusion of all unpublished studies produced a RR of 1.12 for death (95% CI 0.78 to 1.62, P value = 0.53) and a RR of 1.21 for SSAEs (95% CI 1.06 to 1.37, P value = 0.004), indicating a higher risk of SSAEs in those assigned to bevacizumab than ranibizumab. </p> </section> <section id="CD011230-sec-0007"> <h3 class="title" id="CD011230-sec-0007">Authors' conclusions</h3> <p>This systematic review of non‐industry sponsored RCTs could not determine a difference between intravitreal bevacizumab and ranibizumab for deaths, All SSAEs, or specific subsets of SSAEs in the first two years of treatment, with the exception of gastrointestinal disorders. The current evidence is imprecise and might vary across levels of patient risks, but overall suggests that if a difference exists, it is likely to be small. Health policies for the utilisation of ranibizumab instead of bevacizumab as a routine intervention for neovascular AMD for reasons of systemic safety are not sustained by evidence. The main results and quality of evidence should be verified once all trials are fully published. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011230-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011230-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011230-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011230-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011230-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011230-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011230-abs-0003" lang="en"> <h3>Systemic (whole body) safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration </h3> <p><b>Background</b> <br/> Neovascular age‐related macular degeneration (AMD) is a progressive and chronic disease of the eye, and a leading cause of severe blindness in elderly populations. The disease is characterised by the abnormal growth of arteries and veins (neovascularisation) in the macula, a region of the retina (back portion of eye) responsible for central vision. Without treatment, the leakage of these blood vessels causes swelling and damage to the macula, resulting in a fibrous scar that impairs eyesight. Approximately one out of 10 people with neovascular AMD suffer legal blindness, accounting for 90% of all cases of severe vision loss due to AMD. </p> <p>Therapies against neovascular AMD target new blood vessels. Bevacizumab (commercial name Avastin®) and ranibizumab (Lucentis®) are biological drugs that bind to and block the function of vascular endothelial growth factor (VEGF), a protein released by cells in the body that stimulates the growth and leakage of blood vessels. The two drugs, accordingly, inhibit the process of neovascularisation. Ranibizumab is approved to treat neovascular AMD by injection into the eye (intravitreal injection), while bevacizumab is approved as a cancer therapy by injection into the vein through the skin. The two drugs have similar chemical structures and the same mechanism of action. Although their benefits are equivalent, it has been hypothesised that the two drugs have different systemic safety profiles, such that one drug might cause more adverse events (harms) at the level of whole body compared to the other. </p> <p><b>Review question</b> <br/> We evaluated whether the two drugs differed in terms of deaths or serious systemic adverse events (SSAEs) in people with neovascular AMD. The latter refers to medically related events that result in death, are life‐threatening, require hospital admission or prolong hospital stay, or cause persistent or significant disability. </p> <p><b>Study characteristics</b> <br/> We included nine randomised controlled trials (RCTs), none supported by industry, with 3665 participants directly comparing bevacizumab with ranibizumab. Six RCTs were completed and published, two RCTs were completed, but unpublished, and one was still in progress. We were able to include safety information from all trials, accessing both published and unpublished data. </p> <p>Drugs were administered for up to two years according to continuous or discontinuous treatment. In the first, drugs were regularly administered, irrespective of the remission or progression of the disease; the latter involved 'as needed' (pro re nata, PRN) or 'treat‐and‐extend' regimens in which the drug was injected less frequently as long as there was no recurrence of neovascular manifestations. Follow‐up for adverse events occurred at regular intervals up to one or two years, irrespective of continuous or discontinuous treatment. </p> <p>All studies used the approved dosage of ranibizumab (0.5 mg) according to the 'Summary of Product Characteristics', and the dosage of bevacizumab most recommended by ophthalmologists for intravitreal injection (1.25 mg). </p> <p>Three studies excluded patients at high cardiovascular risk. However, four RCTs considered patients at different cardiovascular risks, representing a wide spectrum of risks and routine practice in hospital settings. </p> <p><b>Key results</b> <br/> Our review found the systemic safety of bevacizumab for neovascular AMD to be similar to that of ranibizumab, except for gastrointestinal disorders, which was a part of a secondary analysis. </p> <p>If 1000 people were treated with ranibizumab for one or two years, 34 would die. If treated instead with bevacizumab, between 27 and 53 of them would die. If 1000 people were treated with ranibizumab, 222 would experience one or more SSAEs. If 1000 people were treated instead with bevacizumab, between 200 and 291 would experience such an event. Deaths are likely to be unrelated to the administration of drugs. </p> <p><b>Quality of the evidence</b> <br/> We could not fully assess the quality of three unpublished studies. We rated the overall quality of the evidence as low to moderate because we could not be certain that one drug was better than the other one on many of our outcomes. Another limitation of the studies was the participants who were recruited into them, and the fact that studies may have missed measuring the outcomes of interest in a few individuals that might have experienced a SSAE. Missing information was equally common in participants treated with bevacizumab and those treated with ranibizumab. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011230-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011230-sec-0067">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011230-sec-0099">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011230-sec-0067"></div> <h3 class="title" id="CD011230-sec-0068">Implications for practice</h3> <section id="CD011230-sec-0068"> <p>From the evidence presented in nine randomised controlled trials (RCTs) comprising 3665 participants with neovascular age‐related macular degeneration (AMD), we did not observe evidence of a difference in the relative safety between intravitreal bevacizumab and ranibizumab for deaths, All SSAEs (serious systemic adverse events), or specific subsets of SSAEs in the first one to two years of treatment, with the exception of gastrointestinal disorders Medical Dictionary for Regulatory Activities System Organ Classes (MedDRA SOC). With regard to available data on systemic safety, this review provides no significant evidence to support the preferential use of either bevacizumab or ranibizumab in the treatment of neovascular AMD. </p> <p>In absolute terms, if 1000 people were treated with ranibizumab for one or two years, 34 would die and 222 would experience one or more SSAEs. If 1000 people were treated with bevacizumab for one or two years, then about 37 would die and 240 would experience one or more SSAEs. Overall, these differences are small and consistent with chance variation. </p> <p>We cannot exclude: i) differences larger than 1% and 5% for deaths and All SSAEs that could be important to patients and ii) potential differences in safety across the levels of patient risk. As elderly individuals have a variable risk of SSAEs due to multi‐morbidity and polypharmacy, the use of bevacizumab and ranibizumab should be closely monitored by physicians. Health professionals should recognise the following patient risk factors before exposing patients to bevacizumab: hypertension, left ventricular dysfunction, haemorrhagic events, inherited or acquired coagulopathy, proteinuria, major surgery, and co‐treatment with other drugs that may potentiate the cardiotoxic effects (e.g., anthracyclines) (<a href="./references#CD011230-bbs2-0019" title="CortesJ , CalvoV , Ramirez‐MerinoN , O'ShaughnessyJ , BrufskyA , RobertN , et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta‐analysis. Annals of Oncology2012;23(5):1130‐7. ">Cortes 2012</a>; <a href="./references#CD011230-bbs2-0056" title="SaifMW , MehraR . Incidence and management of bevacizumab‐related toxicities in colorectal cancer. Expert Opinion on Drug Safety2006;5(4):553‐66. ">Saif 2006</a>; <a href="./references#CD011230-bbs2-0067" title="WuS , KimC , BaerL , ZhuX . Bevacizumab increases risk for severe proteinuria in cancer patients. Journal of the American Society of Nephrology2010;21(8):1381‐9. ">Wu 2010</a>). These individual risk factors should be carefully considered, particularly in patients with multiple risk factors (e.g., coagulopathy, nephrotic disease, and heart failure). </p> </section> <h3 class="title" id="CD011230-sec-0069">Implications for research</h3> <section id="CD011230-sec-0069"> <p>The proportion of randomised evidence that has not yet been published is limited (about 25%) (<a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>; <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a>), but highly relevant, and deserves timely public dissemination. Trialists and entities that financially support these trials should consider and encourage quick dissemination of data, pursuing options such as fast‐track publication (<a href="./references#CD011230-bbs2-0047" title="ManzoliL , FlaccoME , D'AddarioM , CapassoL , DeVitoC , MarzuilloC , et al. Non‐publication and delayed publication of randomized trials on vaccines: survey. BMJ2014;348:g3058. ">Manzoli 2014</a>). </p> <p>We do not support the idea of starting new head‐to‐head RCTs. Rather, an individual patient data meta‐analysis might better assess the exact magnitude of the difference by exploring effect‐modifiers such as drug regimen and susceptible patient subgroups, such as those at higher cardiovascular risk. The investigators for the <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> study have made their trial data publicly available and other trial investigators are urged to do the same. Although RCTs are the best tool to investigate both the efficacy and safety of interventions, they continue to show limitations related to the poor reporting of adverse events, as well as their insufficient power to detect the majority of adverse events, even for common adverse events. Complementary information on the occurrence of adverse events may come from observational studies. However, in this setting, observational studies also show limitations. In addition to the concern about potential biases usually associated with observational designs, we anticipate that the large difference in terms of costs between bevacizumab and ranibizumab could affect patient case‐mix, thereby challenging the comparability between groups (<a href="./references#CD011230-bbs2-0013" title="BoscoJL , SillimanRA , ThwinSS , GeigerAM , BuistDS , ProutMN , et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. Journal of Clinical Epidemiology2010;63(1):64‐74. ">Bosco 2010</a>). For the investigation of safety data, pharmacovigilance remains necessary to explore these issues in the general population, which often comprises of potentially more susceptible patients. </p> <p>We believe that our synthesis is a timely and complete summary of the available evidence from RCTs on the relative safety of bevacizumab compared with ranibizumab. We will update the results of this Cochrane Review once new findings are published. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011230-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011230-sec-0015"></div> <div class="table" id="CD011230-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bevacizumab compared with ranibizumab for neovascular age‐related macular degeneration</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with neovascular age‐related macular degeneration </p> <p><b>Intervention:</b> bevacizumab </p> <p><b>Comparison:</b> ranibizumab </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b> </p> <p>Follow‐up: 1 to 2 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> <br/> (27 to 53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b> (0.78 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3338<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious systemic adverse events</b> </p> <p>Follow‐up: 1 to 2 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> <br/> (200 to 291) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> (0.90 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3665<br/> (9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> 1,2,3,4 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infection</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (36 to 69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.34</b> (0.97 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arterial thromboembolic event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> <br/> (21 to 47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> (0.62 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Myocardial infarction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> <br/> (6 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> (0.42 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> <br/> (5 to 19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> (0.42 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal disorders MedDRA class</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> <br/> (16 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.82</b> <br/> (1.04 to 3.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,4,5 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>For all outcomes, we judged the impact of missing data to be unclear: even the low rate of efficacy missing data, which was in the range of 5% to 10% for most studies, could have impacted on rare adverse events differences. However, we considered that a number of studies used an active monitoring for almost all participants across both arms, reducing the chance of missing SSAEs. We did not decrease the overall quality for risk of bias. </p> <p><sup>2</sup>People at high cardiovascular risk were excluded in <a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, <a href="./references#CD011230-bbs2-0007" title="KrebsI , SchmettererL , BoltzA , ToldR , Vecsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA</a>, and <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>. <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>, <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>, <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a>, and <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a> did not report exclusion criteria based on cardiovascular risks, and we considered them to represent a wide spectrum of risks as well as routine practice in secondary care settings. However, it is unclear as to how the results can be applied to high‐risk patients requiring long‐term treatment. We did not decrease the overall quality for indirectness. </p> <p><sup>3</sup>Wide 95% confidence interval considering relative risk and/or absolute events. We did decrease the overall quality for imprecision (‐1). </p> <p><sup>4</sup>The meta‐analytic estimate was sensitive to the exclusion of <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> and <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>, as well as two unpublished studies. We did decrease the overall quality for inconsistency (‐1). </p> <p><sup>5</sup>'Summary of findings' table outcome not pre‐specified in the review protocol. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011230-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011230-sec-0016">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011230-sec-0080">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011230-sec-0016"></div> <section id="CD011230-sec-0017"> <h3 class="title" id="CD011230-sec-0017">Description of the condition</h3> <p>Age‐related macular degeneration (AMD) is a progressive and chronic disease of the retina. According to numerous population–based studies including individuals aged 30 to 97 years, the pooled prevalence of AMD at any stage is 8.7% (95% credible interval (CrI) 4.3% to 17.4%) and the prevalence of late‐stage AMD is 0.4% (CrI 0.2% to 0.8%), with higher prevalence observed in European versus Asian or African populations (e.g., late AMD: 0.5%, 0.3% and 0.4%, respectively) (<a href="./references#CD011230-bbs2-0066" title="WongWL , SuX , LiX , CheungCMG , KleinR , ChengCY , et al. Global prevalence of age‐related macula degeneration and disease burden projection for 2020 and 2040: a systematic review and meta‐analysis. Lancet Global Health2014;2(2):e106‐16. ">Wong 2014</a>). Age is the main risk factor for AMD across ethnic groups: the late stage ranges from 0.1% (95% CrI 0.1% to 0.2%) among individuals aged 50 to 59 years to 3.3% (95% CrI 2.2% to 4.6%) among individuals aged 80 years or more. The global projected cases of AMD in 2040 are 288 million (95% CrI 205 to 399), with the largest number of cases in Asia and Europe (<a href="./references#CD011230-bbs2-0066" title="WongWL , SuX , LiX , CheungCMG , KleinR , ChengCY , et al. Global prevalence of age‐related macula degeneration and disease burden projection for 2020 and 2040: a systematic review and meta‐analysis. Lancet Global Health2014;2(2):e106‐16. ">Wong 2014</a>). </p> <p>In Western countries, AMD is the leading cause of severe, irreversible blindness in individuals over 50 years of age (<a href="./references#CD011230-bbs2-0018" title="ChappelowAV , KaiserPK . Neovascular age‐related macular degeneration: potential therapies. Drugs2008;68(8):1029‐36. ">Chappelow 2008</a>). The loss of visual perception occurs primarily in the late stages of the disease due to neovascular (i.e., wet) AMD, geographic atrophy, or a combination of the two processes (<a href="./references#CD011230-bbs2-0045" title="LimLS , MitchellP , SeddonJM , HolzFG , WongTY . Age‐related macular degeneration. Lancet2012;379(9827):5‐11. ">Lim 2012</a>). In particular, neovascular AMD accounts for 90% of all cases of severe vision loss due to AMD (<a href="./references#CD011230-bbs2-0025" title="FerrisFL , FineSL , HymanL . Age‐related macular degeneration and blindness due to neovascular maculopathy. Archives of Ophthalmology1984;102(11):1640‐42. ">Ferris 1984</a>). In neovascular AMD, blood vessels grow aberrantly into the subretinal, intraretinal, and intrachoroidal space. These abnormal vessels can leak serous fluid, including lipid and blood, causing swelling and damage to the macula (<a href="./references#CD011230-bbs2-0027" title="GreenWR , EngerC . Age‐related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology1993;100(10):1519‐35. ">Green 1993</a>). Without treatment, its natural course will result in a fibrous scar that greatly diminishes central visual capacity. In the UK, the estimated annual incidence of neovascular AMD is 2.3 (95% CrI 1.4 to 4.0) per 1000 women and 1.4 (95% CrI 0.8 to 2.4) per 1000 men (<a href="./references#CD011230-bbs2-0052" title="OwenCG , JarrarZ , WormaldR , CookDG , FletcherAE , RudnickaAR . The estimated prevalence and incidence of late stage age related macular degeneration in the UK. British Journal of Ophthalmology2012;96(5):752‐6. ">Owen 2012</a>). </p> </section> <section id="CD011230-sec-0018"> <h3 class="title" id="CD011230-sec-0018">Description of the intervention</h3> <p>Vascular endothelial growth factor (VEGF) is an angiogenic cytokine that promotes vascular leakage and growth. Its signalling is over expressed in neovascular AMD as well as in some tumours (e.g., colorectal cancer). Accordingly, VEGF inhibitors such as bevacizumab and ranibizumab have been used to block its pathological angiogenesis. Bevacizumab is approved by drug regulatory authorities for intravenous use as a cancer therapy, whereas ranibizumab is approved for intravitreal use in the treatment of neovascular AMD. </p> <p>Bevacizumab and ranibizumab derive from the same anti‐VEGF mouse monoclonal antibody (<a href="./references#CD011230-bbs2-0024" title="FerraraN , DamicoL , ShamsN , LowmanH , KimR . Development of ranibizumab, an anti‐vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age‐related macular degeneration. Retina2006;26(8):859‐70. ">Ferrara 2006</a>), but differ in the monoclonal antibody fragment and glycosylation of proteins (<a href="./references#CD011230-bbs2-0049" title="MeyerCH , HolzFG . Preclinical aspects of anti‐VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye2011;25(6):661‐72. ">Meyer 2011</a>). In intravitreal injections, both drugs can enter systemic circulation, although bevacizumab, a full‐length antibody, exhibits a longer half‐life (<a href="./references#CD011230-bbs2-0011" title="AveryRL , CastellarinAA , SteinleNC , DhootDS , PieramiciDJ , SeeR , et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. British Journal of Ophthalmology 2014 July 7 [Epub ahead of print]. ">Avery 2014</a>). The shared molecular structure and pharmacological profile of the two drugs, as well as bevacizumab's therapeutic utility (<a href="./references#CD011230-bbs2-0014" title="BraithwaiteT , NanjiAA , LindsleyK , GreenbergPB . Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD007325.pub3] ">Braithwaite 2014</a>), have led to the widespread off‐label/unlicensed use of bevacizumab to treat neovascular AMD as a less expensive alternative to ranibizumab (<a href="./references#CD011230-bbs2-0050" title="MillerJW , LeCouterJ , StraussEC , FerraraN . Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology2013;120(1):106‐14. ">Miller 2013</a>). </p> <p>The approved dosage of ranibizumab as indicated in the 'Summary of Product Characteristics' is 0.5 mg. After intravitreal administration, ranibizumab slowly moves into systemic circulation (<a href="./references#CD011230-bbs2-0068" title="XuL , LuT , TuomiL , JumbeN , LuJ , EpplerS , et al. Pharmacokinetics of ranibizumab in patients with neovascular age‐related macular degeneration: a population approach. Investigative Ophthalmology and Visual Science2013;54(3):1616‐24. ">Xu 2013</a>). The dosage of bevacizumab for intravitreal injection most commonly used in published studies is 1.25 mg (<a href="./references#CD011230-bbs2-0035" title="Horsley W. NHS North East Treatment Advisory Group. Bevacizumab (Avastin®)in the management of neovascular age‐related macular degeneration. www.netag.nhs.uk/files/appraisal‐reports/Bevacizumab%20‐Avastin‐%20AMD%20‐%20NETAG%20appraisal%20report%20‐July%202011.pdf (accessed 15 August 2014). ">Horsley 2009</a>), as it is not toxic to the retina (<a href="./references#CD011230-bbs2-0046" title="ManzanoRP , PeymanGA , KhanP , KivilcimM . Testing intravitreal toxicity of bevacizumab (Avastin). Retina2006;26(3):257‐61. ">Manzano 2006</a>) and is approximately 400‐fold less than the intravenous dose used in cancer therapy (<a href="./references#CD011230-bbs2-0058" title="SchmuckerC , EhlkenC , HansenLL , GerdA , AgostiniHT , LelgemannM . Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age‐related macular degeneration: a systematic review. Current Opinion in Ophthalmology2010;21(3):218‐26. ">Schmucker 2010</a>). In fact, when administered intravitreally, only a small fraction of bevacizumab enters systemic circulation (<a href="./references#CD011230-bbs2-0041" title="KimH , RobinsonSB , CsakyKG . FcRn receptor‐mediated pharmacokinetics of therapeutic IgG in the eye. Molecular Vision2009;15:2803‐12. ">Kim 2009</a>; <a href="./references#CD011230-bbs2-0042" title="KrohneTU , EterN , HolzFG , MeyerCH . Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. American Journal of Ophthalmology2008;146(4):508‐12. ">Krohne 2008</a>; <a href="./references#CD011230-bbs2-0062" title="StergiouPK , SymeonidisC , DimitrakosSA . Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization. Acta Ophthalmologica2011;89(3):218‐21. ">Stergiou 2011</a>). Retreatment regimens include continuous (i.e., monthly injections) and discontinuous treatment, including 'as needed' (pro re nata (PRN)) and 'treat‐and‐extend' regimens in which the drug is injected less frequently as long as there is no recurrence of neovascular manifestations. </p> </section> <section id="CD011230-sec-0019"> <h3 class="title" id="CD011230-sec-0019">Why it is important to do this review</h3> <p>The use of bevacizumab or ranibizumab relies on evidence of superiority of one drug over the other. A number of factors will influence the decision, including different profiles for effectiveness, ocular and systemic adverse events, resource use, and the feasibility of the intervention in practice. There is evidence that bevacizumab is associated with a relative improvement in best corrected visual acuity (BCVA) similar to that of ranibizumab (‐1.15 letters; 95% confidence interval (CI) ‐2.82 to 0.51). BCVA outcome favoured a continuous treatment regimen when compared with a discontinuous regimen (‐2.23 letters; 95% CI ‐3.93 to ‐0.53) (<a href="./references#CD011230-bbs2-0017" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ">Chakravarthy 2013</a>). </p> <p>There is limited evidence that bevacizumab might be associated with higher ocular adverse events (risk ratio (RR) 3.1; 95% CI 1.1 to 8.9); however, the absolute rates of serious ocular adverse events (e.g., endophthalmitis, uveitis) were low (≤ 2.1%) (<a href="./references#CD011230-bbs2-0059" title="SchmuckerC , EhlkenC , AgostiniHT , AntesG , RueckerG , LelgemannM , et al. A safety review and meta‐analyses of bevacizumab and ranibizumab: off‐label versus goldstandard. PLoS One2012;7:e42701. ">Schmucker 2012</a>), and may not have related to the drugs, but to the procedure (i.e., intravitreal injection). Most discordant judgements between the two drugs focused on differences in their systemic safety. </p> <p>VEGF has important growth‐promoting and maintenance roles in a variety of cells and tissues, raising concern that these agents may interfere with normal physiology and worsen conditions such as coronary or peripheral arterial diseases. VEGF inhibition in cancer patients treated systemically with bevacizumab, at higher dosages than are given in neovascular AMD, was found to increase the risk of fatal events due to haemorrhage (RR 2.77; 95% CI 1.07 to 7.16), neutropenia (RR 2.37; 95% CI 0.61 to 9.18), and gastrointestinal perforation (RR 2.45; 95% CI 0.63 to 9.51) (<a href="./references#CD011230-bbs2-0053" title="RanpuraV , HapaniS , WuS . Treatment‐related mortality with bevacizumab in cancer patients: a meta‐analysis. JAMA2011;305(5):487‐94. ">Ranpura 2011</a>). Accordingly, concerns have been expressed about the systemic safety of anti‐VEGF drugs, even at the small doses delivered with intravitreal injection (<a href="./references#CD011230-bbs2-0044" title="LimLS , CheungCM , MitchellP , WongTY . Emerging evidence concerning systemic safety of anti‐VEGF agents‐should ophthalmologists be concerned?. American Journal of Ophthalmology2011;152(3):329‐31. ">Lim 2011</a>). </p> <p>Comparison of AMD Treatments Trials (<a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>), the first published large randomised controlled trial (RCT) comparing ranibizumab directly with bevacizumab, reported a statistically significant finding of an excess of serious systemic adverse events (e.g., life‐threatening or resulting in significant patient disability) related to bevacizumab when compared with ranibizumab (RR 1.29; 95% CI 1.01 to 1.66). The publication of results from a second large RCT, Inhibition of VEGF in Age‐related Choroidal Neovascularisation (<a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>) (<a href="./references#CD011230-bbs2-0017" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ">Chakravarthy 2013</a>), and the concomitant meta‐analysis of the <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> and <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a> safety results at two years prompted by the <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a> and <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> data monitoring committees, again showed that the sum of all serious adverse events differed by treatment regimen. However, when serious adverse events were compared by organ system class or by specific adverse events (e.g., arterial thrombotic event), there were no differences between the drugs. These results and their varying interpretations fuelled medical and health policy debates on the off‐label use of bevacizumab as a far less costly alternative to ranibizumab. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011230-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011230-sec-0020">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011230-sec-0084">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011230-sec-0020"></div> <p>To assess the systemic safety of intravitreal bevacizumab (brand name Avastin®; Genentech/Roche) compared with intravitreal ranibizumab (brand name Lucentis®; Novartis/Genentech) in people with neovascular AMD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011230-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011230-sec-0021">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011230-sec-0085">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011230-sec-0021"></div> <section id="CD011230-sec-0022"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011230-sec-0023"> <h4 class="title">Types of studies</h4> <p>We included head‐to‐head randomised controlled trials (RCTs) comparing bevacizumab and ranibizumab in people affected by neovascular age‐related macular degeneration (AMD). We included trials irrespective of the dosage, whether treatment is continuous or discontinuous, or duration of follow‐up. </p> </section> <section id="CD011230-sec-0024"> <h4 class="title">Types of participants</h4> <p>We included people affected by neovascular AMD irrespective of age, sex, or progression of the condition. </p> </section> <section id="CD011230-sec-0025"> <h4 class="title">Types of interventions</h4> <p>We compared the systemic safety of intravitreal bevacizumab (brand name Avastin®; Genentech/Roche) with ranibizumab (brand name Lucentis®; Novartis/Genentech). For this review, we did not consider placebo‐controlled trials and trials comparing other anti‐vascular endothelial growth factor (VEGF) agents approved for neovascular AMD (e.g., pegaptanib and aflibercept). These studies can contribute to a large network meta‐analysis that simultaneously summarises direct evidence (which comes from studies directly randomising treatments of interest) and indirect evidence (which comes from studies comparing treatments of interest with placebo) (<a href="./references#CD011230-bbs2-0057" title="SalantiG , HigginsJP , AdesAE , IoannidisJP . Evaluation of networks of randomized trials. Statistical Methods in Medical Research2008;17(3):279‐301. ">Salanti 2008</a>). We will be completing the network meta‐analysis as a second phase of this project, to address the issue of the relative effectiveness and safety across a network of RCTs testing anti‐VEGF agents. </p> </section> <section id="CD011230-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD011230-sec-0027"> <h5 class="title">Primary outcomes</h5> <p>Primary outcome domains included:</p> <p> <ol id="CD011230-list-0001"> <li> <p>All‐cause deaths.</p> </li> <li> <p>All serious systemic adverse events (hereinafter referred to as All SSAEs), the sum of individuals affected by one or more SSAEs recorded in a trial. The International Conference on Harmonisation Good Clinical Practice (ICH GCP) Guideline defines SSAEs as medical occurrences that result in death, are life‐threatening, require hospital admission or prolongation of hospital stay, cause persistent or significant disability/incapacity, or are medically important events or reactions (<a href="./references#CD011230-bbs2-0036" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Introductory guide MedDRA version 17.0. www.meddra.org/sites/default/files/guidance/file/intguide_17_0_english.pdf (accessed 13 July 2014). ">ICH 2014</a>). We accepted the definition of SSAE adopted by the study authors, while recognising that some studies may not have adopted the ICH GCP Guideline. </p> </li> </ol> </p> </section> <section id="CD011230-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcome domains included:</p> <p> <ol id="CD011230-list-0002"> <li> <p>Myocardial infarction (MI).</p> </li> <li> <p>Stroke.</p> </li> <li> <p>Arteriothrombotic event, defined as any participant who has experienced at least one of the following events: a) myocardial infarction, b) non‐haemorrhaging stroke, c) angina, d) ischaemic heart disease, e) thrombosis, or f) death from cardiovascular diseases. </p> </li> <li> <p>Serious haemorrhage as defined by each study, including, but not limited to, cerebral, pulmonary, and gastrointestinal haemorrhage (these are usually defined as a haemorrhage that is associated with anaemia, transfusion, haemostatic intervention, hospitalisation, or fatal bleeding). </p> </li> <li> <p>Serious neutropenia as defined by each study (these are usually defined as neutropenia of grade 3 and 4 associated with sepsis and life‐threatening infections) (<a href="./references#CD011230-bbs2-0051" title="National Cancer Institute. Cancer Therapeutics Evaluation Program. Common Toxicity Criteria for Adverse Events. 3rd Edition. Bethesda, MD: National Cancer Institute, 2003. ">National Cancer Institute 2003</a>). </p> </li> <li> <p>Gastrointestinal perforation.</p> </li> <li> <p>Serious infection as defined by each study, including, but not limited to, pneumonia, lung abscess, and pyothorax (these are usually defined as an infection associated with the use of intravenous antibiotic, hospitalisation, intubation, or death). We excluded ocular infections. </p> </li> <li> <p>Treatment‐related drug discontinuation.</p> </li> <li> <p>SSAEs classified according to the Medical Dictionary for Regulatory Activities System Organ Classes (MedDRA SOC) (version 17.0) (<a href="./references#CD011230-bbs2-0036" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Introductory guide MedDRA version 17.0. www.meddra.org/sites/default/files/guidance/file/intguide_17_0_english.pdf (accessed 13 July 2014). ">ICH 2014</a>), including: benign, malignant, or unspecified neoplasms; cardiovascular disorders; gastrointestinal disorders; general disorders and administration site conditions; infections and infestations; nervous system disorders; and respiratory, thoracic, and mediastinal disorders. </p> </li> <li> <p>Serious adverse events previously associated with drugs affecting the VEGF pathway (i.e., arteriothrombotic events, systemic haemorrhage, congestive heart failure, venous thrombotic events, hypertension, and vascular death). </p> </li> </ol> </p> <p>The SSAEs classified by MedDRA SOC differed from our primary outcome All SSAEs as they explored specific subsets of SSAEs, providing the opportunity to explore the biological plausibility of each. </p> </section> </section> </section> <section id="CD011230-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011230-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We systematically searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 1), Ovid MEDLINE, (January 1946 to March 2014) and EMBASE (January 1980 to March 2014). We used and updated the search strategy prepared for an update of a Cochrane Review on antiangiogenic drug effectiveness for neovascular AMD (<a href="./references#CD011230-bbs2-0061" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3] ">Solomon 2014</a>). RCTs that investigated an anti‐VEGF treatment compared to another treatment, sham treatment, or no treatment were eligible. We also searched clinical trial registers, including the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en" target="_blank">www.who.int/ictrp/search/en</a>) to identify other ongoing studies or completed studies that have not yet been published. We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 27 March 2014. For unpublished RCTs, we searched the Internet for pre‐publication study presentations at conferences or meetings and contacted study authors seeking information on safety data. </p> </section> <section id="CD011230-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of relevant studies to identify additional studies.</p> </section> </section> <section id="CD011230-sec-0032"> <h3 class="title" id="CD011230-sec-0032">Data collection and analysis</h3> <p>We collected and combined outcomes at the maximum follow‐up times reported up to a maximum of two years, since this corresponds to the maximal cumulative drug dosage. We conducted a pre‐specified subgroup analysis to explore SSAE outcome at the one‐year follow‐up. </p> <section id="CD011230-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Two investigators (EL and GV) independently screened the titles and abstracts of studies identified through the literature searches and additional sources. We retrieved and independently assessed the full text or unpublished reports using predefined inclusion criteria. We resolved discrepancies through discussion and, when necessary, by consulting an additional investigator (LM). </p> </section> <section id="CD011230-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>Two investigators independently extracted data (EL and GV) on study characteristics and entered data into RevMan (<a href="./references#CD011230-bbs2-0054" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Three investigators extracted data on our safety primary and secondary outcomes (EL, GV, and KK). </p> </section> <section id="CD011230-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in each included study following the criteria outlined in Chapter 8 of the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011230-bbs2-0034" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.cochrane‐handbook.org. ">Higgins 2011</a>), which addresses the following key domains: randomisation sequence generation; allocation concealment; masking (blinding) of participants, trial personnel, and outcome assessors; incomplete outcome data; selective outcome reporting (i.e., absence of data or non‐publication of deaths and All SSAEs ‐ our primary outcomes); and other sources of bias (e.g., early termination of a trial due to benefits or the failure of authors to disclose the study's source of financial support). </p> <p>We evaluated additional risk of bias items specific to adverse events using the following items: (1) adverse event definition: if the definition of adverse events was pre‐specified in the protocol and collected based on standard criteria or classification system (e.g., MedDRA SOC) and (2) method of adverse event assessment: if the researchers actively monitored for adverse events or simply provided spontaneous reporting of adverse events that arose during the study. </p> <p>If the information in published study reports or unpublished supporting documents (e.g., meeting abstracts or presentations) was partial or inadequate to assess the risk of bias, we contacted the study authors for clarification. If the authors did not respond, we assessed the risk of bias based on the available information. </p> </section> <section id="CD011230-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>We used the risk ratio (RR) to estimate the relative safety effect of the two anti‐VEGF drugs. </p> </section> <section id="CD011230-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>Individual participants served as the unit of analysis. Since repeated SSAEs can occur in the same participant, we considered the number of individuals with at least one SSAE, rather than the number of SSAEs. However, the individual‐level analysis might decrease the statistical power of meta‐analyses. </p> </section> <section id="CD011230-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>In all studies, we carried out the analyses, as far as possible, on an intention‐to‐treat basis. In other words, we attempted to include all participants randomised to each group in the analyses, irrespective of the treatment received or if the participants completed the study follow‐up (<a href="./references#CD011230-bbs2-0010" title="AklEA , JohnstonBC , Alonso‐CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One2013;8(2):e57132. ">Akl 2013</a>). As a second option, we collected data on participants who received at least one dose of study medication: as treated analysis. </p> <p>If there was a discrepancy between the number randomised and the number analysed in each treatment group, we calculated and reported the percentage lost to follow‐up in each group. Where data were inadequate to assess the extent of SSAEs, we contacted the principal investigators of included studies to provide any unreported data. Where it was not possible to obtain information on missing data, we recorded this in the data collection form and reported it in the 'Risk of bias' table. We further discussed the extent to which the missing data could alter the results/conclusions of the review. </p> </section> <section id="CD011230-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>We anticipated that a low number of RCTs in a pairwise comparison (due to either the paucity of studies in the field or incomplete reporting) would prevent the formal assessment of statistical heterogeneity. Nevertheless, we calculated the Chi<sup>2</sup> and I<sup>2</sup> statistics. For the latter, we also calculated and reported the 95% CI for primary outcomes. I<sup>2</sup> estimates the variability among individual study relative risk estimates that is due to statistical heterogeneity rather than to sampling error (<a href="./references#CD011230-bbs2-0033" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD011230-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>We anticipated that a low number of RCTs in a pairwise comparison would also prevent the formal assessment of publication bias. </p> </section> <section id="CD011230-sec-0041"> <h4 class="title">Data synthesis</h4> <p>In this context, we reasoned that there may be true differences across the population of potential studies as they may have enrolled participants at different risk levels for adverse events. For instance, some studies might have included participants at high risk for arteriothrombotic events, while others may have excluded such participants. For this reason, we used a Mantel‐Haenszel random‐effects model for meta‐analyses, which provides a robust estimate when pooling sparse data (<a href="./references#CD011230-bbs2-0055" title="RobinsJ , BreslowN , GreenlandS . Estimators of the Mantel‐Haenszel variance consistent in both sparse data and large‐strata limiting models. Biometrics1986;42(2):311‐23. ">Robins 1986</a>). We did not formally adjust for multiplicity of comparisons, but considered this issue when interpreting the analyses. </p> <section id="CD011230-sec-0042"> <h5 class="title">'Summary of findings' table</h5> <p>We summarised the strength of evidence for all‐cause deaths, All SSAEs, serious systemic infections, arterial thromboembolic events, myocardial infarctions, and strokes, using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology (<a href="./references#CD011230-bbs2-0028" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). We used an iterative electronic correspondence discussion process to reach consensus on: a) the factors that affect confidence in the estimate of effects, including risk of bias (i.e., design and study limitations), imprecision, indirectness (directness in the GRADE approach includes generalisability and applicability), inconsistency of results (i.e., heterogeneity), magnitude of effect, and issues of residual plausible confounding and b) the rating of the evidence. We expected the imprecision of RRs to be a limitation when investigating deaths and adverse events in RCTs, which might be rare, therefore we followed the GRADE guidelines for assessing this quality item (<a href="./references#CD011230-bbs2-0029" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011a</a>; <a href="./references#CD011230-bbs2-0030" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence‐imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011b</a>). We focused on the 95% CI around the absolute effects, considering a follow‐up between one and two years as sufficient. We adopted an absolute minimal difference of 1% for deaths and 5% for All SSAEs as clinically relevant. When the 95% CI included treatment effects above these thresholds and, therefore, did not exclude an absolute detrimental effect appreciably less than 1% and 5%, we evaluated the precision as insufficient and downgraded the quality of the overall evidence. We adopted these thresholds based on rating imprecision guidelines (<a href="./references#CD011230-bbs2-0030" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence‐imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011b</a>), as well as our own judgement. We settled a clinical decision threshold boundary of 1% absolute difference as we reasoned this difference to be important to both patients and health systems. For example, when the absolute difference in death rates between ranibizumab and bevacizumab was very small (absolute difference of 0.3% with a 95% CI ranging from ‐0.1% to 0.7%), the results of the meta‐analysis excluded an important difference favouring either drug, and we did not downgrade the quality of evidence for deaths. We adopted two different imprecision thresholds, 1% or 5%, because the differing importance of the outcome deaths or serious adverse events influenced our judgement. </p> <p>We presented the overall evidence in a 'Summary of findings' table with summary estimates of absolute and relative effects and their quality according to the GRADE methodology (<a href="./references#CD011230-bbs2-0031" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. ">Guyatt 2013</a>). For each outcome, we categorised our confidence in the estimate of effect as one of four levels, ranging from very low to high. </p> </section> </section> <section id="CD011230-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not plan a subgroup analysis for this review.</p> </section> <section id="CD011230-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We computed a Mantel‐Haenszel RR using a fixed‐effect model to investigate any influence of small study effects on the pooled RR, since the random‐effects model tends to attribute greater weight to small studies with increasing heterogeneity (<a href="./references#CD011230-bbs2-0063" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at www.cochrane‐handbook.org. ">Sterne 2011</a>). </p> <p>We performed a sensitivity analysis, excluding unpublished data, as well as a leave‐one‐out meta‐analysis to assess the independent influence of each study on the summary estimate (<a href="./references#CD011230-bbs2-0065" title="TobiasA . Assessing the influence of a single study in the meta‐analysis estimate. Stata Technical Bulletin1999;8:1‐48. ">Tobias 1999</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011230-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011230-sec-0045"></div> <section id="CD011230-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD011230-sec-0047"> <h4 class="title">Results of the search</h4> <p><a href="#CD011230-fig-0001">Figure 1</a> illustrates the process by which studies were selected for inclusion in our meta‐analysis. </p> <div class="figure" id="CD011230-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for screened, included, and excluded study reports" data-id="CD011230-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for screened, included, and excluded study reports</p> </div> </div> </div> </section> <section id="CD011230-sec-0048"> <h4 class="title">Included studies</h4> <p>Refer to <a href="./references#CD011230-sec-0079" title="">Characteristics of included studies</a>. Nine RCTs (3665 participants) met our eligibility criteria. Of these, six RCTs were completed and published (<a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>; <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a>; <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>; <a href="./references#CD011230-bbs2-0007" title="KrebsI , SchmettererL , BoltzA , ToldR , Vecsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA</a>; <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>), comprising a total of 1362 participants treated with bevacizumab and 1383 treated with ranibizumab. <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> and <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a> provided data at two years (<a href="./references#CD011230-bbs2-0017" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ">Chakravarthy 2013</a>; <a href="./references#CD011230-bbs2-0048" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. ">Martin 2012</a>), which we used for the primary analyses, whereas the remaining four studies provided data at a maximum follow‐up of one year. Three RCTs were unpublished: two were completed (<a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>), and one is still ongoing (<a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a>). Unpublished data comprised a total of 482 participants treated with bevacizumab and 438 treated with ranibizumab. We extracted the unpublished data of <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a> from a presentation given by the principal investigator at the American Academy of Ophthalmology Retina Subspecialty meeting in 2014. Although this presentation provided information on death and individual cardiovascular SSAE, it did not report the total number of All SSAEs as defined by the study authors. Accordingly, we derived the total number of All SSAEs from the sum of all mutually exclusive SSAEs. We contacted the principal investigator of <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a> and requested data on this outcome; however, the investigator declined to provide additional information until the trial's publication. We extracted the unpublished data of <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a> from a presentation at the 2014 meeting of the Association for Research in Vision and Ophthalmology. We contacted the principal investigator of <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a> to obtain additional data, but did not receive a response. Unpublished data of <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a> were provided by the study authors. Two studies were conducted in the USA (<a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>; <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>), six in Europe (<a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a>; <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>; <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>; <a href="./references#CD011230-bbs2-0007" title="KrebsI , SchmettererL , BoltzA , ToldR , Vecsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA</a>; <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a>), and one in India (<a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>). Studies included populations at variable baseline cardiovascular risks. The proportion of <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> participants who had a prior history of MI, stroke, and transient ischaemic attack at baseline were 12%, 6%, and 6% of the cases, respectively. These figures were lower in <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a> (4%, 4%, and &lt; 0.5%) and <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a> (7.5%, 2.3%, and 5%), while <a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, <a href="./references#CD011230-bbs2-0007" title="KrebsI , SchmettererL , BoltzA , ToldR , Vecsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA</a>, and <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a> excluded participants with a previous history of vascular thromboembolic events. All trials were non‐industry sponsored. </p> </section> <section id="CD011230-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We did not exclude any head‐to‐head RCTs in this review.</p> </section> </section> <section id="CD011230-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for each study is presented in <a href="#CD011230-fig-0002">Figure 2</a>. Two unpublished studies were at unclear risk of bias for all items (<a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>), since limited information was available and the trial authors declined our request for additional information. It is important to note that our 'Risk of bias' assessment differed from that conducted in the parallel efficacy review (<a href="./references#CD011230-bbs2-0061" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3] ">Solomon 2014</a>, update under peer review) due to the two reviews' differing outcomes of interest, access to additional information (i.e., from trial authors), and use of additional 'Risk of bias' dimensions related to adverse events. </p> <div class="figure" id="CD011230-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011230-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011230-sec-0051"> <h4 class="title">Allocation</h4> <p>The remaining studies generally reported details about random sequence generation and allocation concealment. The treatment allocation was described as masked to clinicians and participants in seven studies (<a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>; <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a>; <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>; <a href="./references#CD011230-bbs2-0007" title="KrebsI , SchmettererL , BoltzA , ToldR , Vecsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA</a>; <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>; <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a>). </p> </section> <section id="CD011230-sec-0052"> <h4 class="title">Blinding</h4> <p>In <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>, about half of the participants treated with ranibizumab and a quarter of those treated with bevacizumab may have been aware of their drug assignment through billing reports, while a negligible fraction of participants were unmasked in <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>. <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a> used double‐masking. In <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a> and <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>, investigators did not report any issue with masking, while we could not find information about the other trials. </p> </section> <section id="CD011230-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>We contacted study authors for additional information about the risk of bias concerning the missing outcome data: this seemed to be a potential problem across studies since even low rates of missing data, which were between 5% and 10% at the end of follow‐up in all studies, could impact estimates for the relative risk of SSAEs. Nevertheless, the opportunity to miss SSAEs during the maintenance period was unlikely to have occurred since all studies, except <a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, had active SSAE monitoring between injections. Furthermore, missing data were equally distributed between arms, except <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>, in which more information was missing from the bevacizumab arm (35 versus 21 missing data). </p> </section> <section id="CD011230-sec-0054"> <h4 class="title">Selective reporting</h4> <p>All studies measured our primary outcomes. Although <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>, <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>, and <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a> have not yet been published, we were able to collect data about deaths and All SSAEs. </p> </section> <section id="CD011230-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>One trial was closed prematurely due to poor recruitment (<a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>), a common reason for the discontinuation of RCTs (<a href="./references#CD011230-bbs2-0040" title="KasendaB , vonElmE , YouJ , BlumleA , TomonagaY , SaccilottoR , et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA2014;311(10):1045‐51. ">Kasenda 2014</a>). Although empirical evidence demonstrates that discontinued RCTs, on average, overestimate treatment effects, biases are usually associated with RCTs that have been prematurely discontinued for superiority (<a href="./references#CD011230-bbs2-0012" title="BasslerD , MontoriVM , BrielM , GlasziouP , WalterSD , RamsayT , et al. Reflections on meta‐analyses involving trials stopped early for benefit: is there a problem and if so, what is it?. Statistical Methods in Medical Research2013;22(2):159‐68. ">Bassler 2013</a>). Accordingly, we decided to rate this study at unclear risk of bias. </p> <section id="CD011230-sec-0056"> <h5 class="title">Risk of bias related to adverse events</h5> <p>Published studies (<a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>; <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a>; <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>) and <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a> appeared to have implemented an appropriate, pre‐specified definition of SSAEs and actively monitored them, except for <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a> that did not use a pre‐specified definition of SSAEs, but actively monitored participants for signs and symptoms possibly related to adverse events, and <a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a> and <a href="./references#CD011230-bbs2-0007" title="KrebsI , SchmettererL , BoltzA , ToldR , Vecsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA</a>, for which both the definition and monitoring of SSAEs were unclear. </p> </section> </section> </section> <section id="CD011230-sec-0057"> <h3 class="title" id="CD011230-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD011230-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD011230-sec-0058"> <h4 class="title">Adverse events with bevacizumab compared with ranibizumab</h4> <p><a href="#CD011230-fig-0003">Figure 3</a> shows the summary risk ratio (RR) for deaths from eight studies, comprising 3338 participants. The RR of all‐cause death for bevacizumab compared with ranibizumab is 1.10 (95% confidence interval (CI) 0.78 to 1.57, P value = 0.58). Between‐study statistical heterogeneity was low (I<sup>2</sup> = 0%; 95% CI 0% to 71%; <a href="./references#CD011230-fig-0005" title="">Analysis 1.1</a>). </p> <div class="figure" id="CD011230-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Bevacizumab versus ranibizumab, primary analysis at longest follow‐up, outcome: 1.1 All‐cause death." data-id="CD011230-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bevacizumab versus ranibizumab, primary analysis at longest follow‐up, outcome: 1.1 All‐cause death. </p> </div> </div> </div> <p><a href="#CD011230-fig-0004">Figure 4</a> shows the summary RR for All SSAEs (serious systemic adverse events) from nine studies, comprising 3665 participants. The RR of All SSAEs in bevacizumab compared with ranibizumab is 1.08 (95% CI 0.90 to 1.31, P value = 0.42) (<a href="./references#CD011230-fig-0006" title="">Analysis 1.2</a>). Heterogeneity was moderate (I<sup>2</sup> = 41%; 95% CI 0% to 74%). </p> <div class="figure" id="CD011230-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Bevacizumab versus ranibizumab, longest follow‐up, outcome: 1.2 All serious systemic adverse events." data-id="CD011230-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bevacizumab versus ranibizumab, longest follow‐up, outcome: 1.2 All serious systemic adverse events. </p> </div> </div> </div> <p>None of the studies reported serious gastrointestinal perforation, neutropenia, and treatment‐related drug discontinuations. We extracted six secondary outcomes from six studies: arterial thromboembolic events, infections, myocardial infarctions, non‐ocular haemorrhages, strokes, and vascular events associated with anti‐VEGF treatment. We did not find any statistically significant difference in secondary outcomes between bevacizumab and ranibizumab (<a href="./references#CD011230-fig-0007" title="">Analysis 1.3</a>; <a href="./references#CD011230-fig-0008" title="">Analysis 1.4</a>; <a href="./references#CD011230-fig-0009" title="">Analysis 1.5</a>; <a href="./references#CD011230-fig-0010" title="">Analysis 1.6</a>; <a href="./references#CD011230-fig-0011" title="">Analysis 1.7</a>; <a href="./references#CD011230-fig-0012" title="">Analysis 1.8</a>; <a href="./references#CD011230-fig-0013" title="">Analysis 1.9</a>; Analysis 1.10; <a href="./references#CD011230-fig-0014" title="">Analysis 1.11</a>; <a href="./references#CD011230-fig-0015" title="">Analysis 1.12</a>; <a href="./references#CD011230-fig-0017" title="">Analysis 1.14</a>: <a href="./references#CD011230-fig-0018" title="">Analysis 1.15</a>; <a href="./references#CD011230-fig-0019" title="">Analysis 1.16</a>; <a href="./references#CD011230-fig-0020" title="">Analysis 1.17</a>): all comparisons gave estimates with wide CIs with the exception of gastrointestinal disorders MedDRA SOC (RR 1.82; 95% CI 1.04 to 3.19) (<a href="./references#CD011230-fig-0016" title="">Analysis 1.13</a>). </p> <p>The main results should be verified once <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>, <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>, and <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a> are fully published. </p> <section id="CD011230-sec-0059"> <h5 class="title">Sensitivity and subgroup analyses</h5> <p>The one‐year random‐effects estimates for the relative risk of death (RR 1.23; 95% CI 0.72 to 2.10, P value = 0.45) (<a href="./references#CD011230-fig-0021" title="">Analysis 2.1</a>) and the relative risk of All SSAEs (RR 1.11; 95% CI 0.90 to 1.37, P value = 0.33) (<a href="./references#CD011230-fig-0022" title="">Analysis 2.2</a>) in participants assigned to bevacizumab versus ranibizumab were consistent with estimates derived at the end of the longer follow‐up. </p> <p>Influence (leave‐one‐out) analyses did not show any influential studies on the RR for death. For All SSAEs, the influence analysis showed that our results were influenced by <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> and <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>. The exclusion of <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> moved the overall estimate towards no difference (RR 1.01; 95% CI 0.82 to 1.25, P value = 0.92) (<a href="./references#CD011230-fig-0023" title="">Analysis 3.1</a>). The exclusion of <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a> from the analysis of All SSAEs resulted in a larger RR, with more SSAEs in the bevacizumab group, largely driven by <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> (RR 1.19; 95% CI 1.06 to 1.34, P value = 0.004) (<a href="./references#CD011230-fig-0024" title="">Analysis 4.1</a>). The exclusion of all unpublished studies (<a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>; <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a>) yielded a RR of 1.12 for death (95% CI 0.78 to 1.62, P value = 0.53) (<a href="./references#CD011230-fig-0025" title="">Analysis 5.1</a>) and a RR of 1.21 for SSAEs (95% CI 1.06 to 1.37, P value = 0.004) (<a href="./references#CD011230-fig-0026" title="">Analysis 5.2</a>), indicating a higher risk of SSAEs in those assigned to bevacizumab than ranibizumab. For <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a> and <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>, we were unable to obtain the full definitions of SSAEs and their methods of assessment (see 'Risk of bias' assessment). </p> <p>Using a fixed‐effect meta‐analysis model for primary and secondary outcomes on the same studies (<a href="./references#CD011230-fig-0027" title="">Analysis 6.1</a>; <a href="./references#CD011230-fig-0029" title="">Analysis 6.3</a>; <a href="./references#CD011230-fig-0030" title="">Analysis 6.4</a>; <a href="./references#CD011230-fig-0031" title="">Analysis 6.5</a>; <a href="./references#CD011230-fig-0032" title="">Analysis 6.6</a>; <a href="./references#CD011230-fig-0033" title="">Analysis 6.7</a>; <a href="./references#CD011230-fig-0034" title="">Analysis 6.8</a>; <a href="./references#CD011230-fig-0035" title="">Analysis 6.9</a>; Analysis 6.10; <a href="./references#CD011230-fig-0036" title="">Analysis 6.11</a>; <a href="./references#CD011230-fig-0037" title="">Analysis 6.12</a>; <a href="./references#CD011230-fig-0039" title="">Analysis 6.14</a>; <a href="./references#CD011230-fig-0040" title="">Analysis 6.15</a>; <a href="./references#CD011230-fig-0041" title="">Analysis 6.16</a>; <a href="./references#CD011230-fig-0042" title="">Analysis 6.17</a>), we did not find a statistically significant difference between the drugs for deaths. The fixed‐effect meta‐analysis estimate of All SSAEs was statistically significant (RR 1.12; 95% CI 1.00 to 1.26, P value = 0.04) (<a href="./references#CD011230-fig-0028" title="">Analysis 6.2</a>). The meta‐analysis was dominated by a single study, <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> (weight = 46.9%). Again, the estimate of gastrointestinal problems was statistically significant and favoured ranibizumab (RR 1.93; 95% CI 1.20 to 3.11, P value = 0.007) (<a href="./references#CD011230-fig-0038" title="">Analysis 6.13</a>). </p> </section> <section id="CD011230-sec-0060"> <h5 class="title">Quality of the evidence</h5> <p>Refer to <a href="./full#CD011230-tbl-0001">summary of findings Table for the main comparison</a> for the quality of the evidence for each outcome. In addition to the a priori selected outcomes, we decided also to report the gastrointestinal Medical Dictionary for Regulatory Activities System Organ Classes (MedDRA SOC), the only statistically significant difference we found. Based on the event rates in the studies, the absolute difference between the two drugs is 0.3% in death rates with a 95% CI ranging from ‐0.8% to 1.9%, and 1.8% in All SSAEs rates with a 95% CI from ‐2.2% to 6.9%. The results of this systematic review do not exclude differences larger than 1% and 5% for deaths and All SSAEs that could be important to patients. For gastrointestinal disorders MedDRA SOC, the absolute difference is 1.3% with more events in the bevacizumab arm and a 95% CI ranging from 1.3% to 3.4%. Using GRADE, we assessed the overall quality of the evidence. We began with a GRADE score of four points as the total evidence derives from nine RCTs. We then addressed potential reasons to rate down or up the overall quality of evidence. We downgraded the evidence due to uncertainties in the absolute risks for all outcomes, subtracting one point from the total score for imprecision. We subtracted an additional point for inconsistency as the meta‐analysis of All SSAEs was sensitive to the exclusion of <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> or unpublished studies (<a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>; <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a>) which, together with the moderate I<sup>2</sup> value in the main analysis, we interpreted as evidence of heterogeneity. Thus, the evidence suggests that the true relative safety of bevacizumab versus ranibizumab could be different from that observed in our overall estimates. </p> <p>The quality of evidence should be reassessed once <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>, <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>, and <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a> are fully published. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011230-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011230-sec-0061">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011230-sec-0093">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011230-sec-0061"></div> <section id="CD011230-sec-0062"> <h3 class="title" id="CD011230-sec-0062">Summary of main results</h3> <p>Our systematic review on the systemic safety of bevacizumab directly compared with ranibizumab at one to two years of follow‐up in randomised controlled trials (RCTs) on people with neovascular age‐related macular degeneration (AMD) did not find conclusive or compelling evidence of an increased or decreased risk of deaths and serious systemic adverse events (SSAEs) ‐ an outcome with qualifying events of death, life‐threatening events, hospitalisation, and disability. Although one of our primary outcomes was composite, performed to gain statistical power to show any effects on SSAEs, the 95% confidence interval (CI) around the pooled estimate of risk ratio (RR) included unity, from 0.90 to 1.31. With the exception of gastrointestinal disorders, RR estimates for secondary outcomes did not indicate statistically significant differences between bevacizumab and ranibizumab, although the point estimates were imprecise. For instance, a few more events were registered in the bevacizumab arm for the cardiac disorder Medical Dictionary for Regulatory Activities System Organ Classes (MedDRA SOC), while a few more events were registered in the ranibizumab arm for myocardial infarction or stroke, with negligible differences. Gastrointestinal disorders were classified according to the MedDRA SOC, which includes abdominal pain, colitis, Crohn's disease, duodenal ulcer, dyspepsia, faecaloma, intestinal obstruction, intestinal perforation, pancreatitis, and vomiting. The rate of these events was low in both groups (1.6% for ranibizumab and 2.9% for bevacizumab). The components of this outcome have different clinical importance, with gastrointestinal perforation as one of the most clinically relevant adverse events. Gastrointestinal perforation has been recognised with the systemic use of bevacizumab in patients with cancer (<a href="./references#CD011230-bbs2-0022" title="electronic Medicines Compendium(eMC) . Avastin 25mg/ml concentrate for solution for infusion. www.medicines.org.uk/emc/medicine/15748 (accessed 31 July 2014). ">eMC 2014</a>; <a href="./references#CD011230-bbs2-0032" title="HapaniS , ChuD , WuS . Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta‐analysis. The Lancet. Oncology.2009;10(6):559‐68. ">Hapani 2009</a>), but its incidence was limited (0.9%; 95% CI 0.7% to 1.2%). It remains unclear whether low‐dose ocular administration might or might not cause similar harms. We were unable to collect data on the effect of the drugs on gastrointestinal perforation as well as other outcomes of interest, such as severe neutropenia, since they were reported in only one study. </p> <p>Initial reports of studies exploring the relative safety of bevacizumab and ranibizumab indicated a possible increased risk for bevacizumab (<a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>), with subsequent studies showing no increased risk (<a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a>; <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>; <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>; <a href="./references#CD011230-bbs2-0007" title="KrebsI , SchmettererL , BoltzA , ToldR , Vecsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA</a>; <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>; <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a>), therefore the sequence of findings conforms to what has been called the Proteus phenomenon (<a href="./references#CD011230-bbs2-0038" title="IoannidisJP , TrikalinosTA . Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. Journal of Clinical Epidemiology2005;58(6):543‐9. ">Ioannidis 2005a</a>). However, diverging from the Proteus phenomenon, in which the first trial is small and opportunistic, in our context the <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> study is a large RCT that is considered a major breakthrough of independent research. Moreover, it is not uncommon for there to be conflicting results between a large RCT and meta‐analyses on the same topic (<a href="./references#CD011230-bbs2-0043" title="LeLorierJ , GrégoireG , BenhaddadA , LapierreJ , DerderianF . Discrepancies between meta‐analyses and subsequent large randomized, controlled trials. New England Journal of Medicine1997;337(8):536‐42. ">LeLorier 1997</a>). Reasons for these discrepancies include different patient populations: CATT may have included patients with diverse baseline risks for SSAEs compared with other included RCTs. Additionally, a few patients at high risks may greatly influence the overall estimate (<a href="./references#CD011230-bbs2-0037" title="IoannidisJP , LauJ . The impact of high‐risk patients on the results of clinical trials. Journal of Clinical Epidemiology1997;50(10):1089‐98. ">Ioannidis 1997</a>): CATT accounts for the majority of the SSAEs of interest recorded in our meta‐analysis, as shown in our leave‐one‐out sensitivity analysis. There are two possible interpretations of these findings. First, the safety of the two drugs is not the same across different levels of patient risk. However, trials that also included patients at high risks did not replicate CATT findings (<a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>; <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a>; <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>). Second, the two drugs have the same safety for all patients, and the reasons for differences relate to the limitations of individual trials. The CATT investigators carefully considered the potential failure of their masking efforts: through billing documents, patients and health professionals may have known the intervention assigned. This ancillary information might have led to disproportionate and varying levels of attention to SSAEs in patients by health professionals. Our study calls for a more cautious interpretation of the <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> SSAE finding: the result of one trial is not substantially significant and certain enough to activate drug policies (i.e., restricted reimbursement for the off‐label use of medicines). Instead, we urge decision‐makers to evaluate the result based on its substantive robustness and replicability, components that a community with rational standards for interpreting evidence would agree are necessary for a result to be considered relevant and objective, beyond merely statistically significant, to guide political action (<a href="./references#CD011230-bbs2-0023" title="EsareyJ , DannemanN . A quantitative method for substantive robustness assessment. jee3.web.rice.edu/riskstats.pdf (accessed 20 August 2014). ">Esarey 2014</a>; <a href="./references#CD011230-bbs2-0039" title="IoannidisJP . Contradicted and initially stronger effects in highly cited clinical research. JAMA2005;294(2):218‐28. ">Ioannidis 2005b</a>). </p> <p>Our sensitivity analysis, adopting a fixed‐effect, featured a marginal statistically significant difference (P value = 0.04) favouring ranibizumab in terms of SSAEs. However, under the assumption that no between‐study heterogeneity existed, the weight of CATT became more prominent. For the above reasons, we qualitatively judged the fixed‐effect model assumption to be too strong given the potential differences between the trials in eligibility criteria (inclusion of high‐risk patients or not), baseline disease severity of patient populations, follow‐up duration (one or two years), and successful masking of participants, investigators, and assessors, with moderate between‐study heterogeneity present in the SSAE analysis (I<sup>2</sup> = 41%). </p> </section> <section id="CD011230-sec-0063"> <h3 class="title" id="CD011230-sec-0063">Overall completeness and applicability of evidence</h3> <p>Health professionals and decision‐makers should consider the following factors when interpreting the results of this review: </p> <p> <ol id="CD011230-list-0003"> <li> <p>We found nine non‐industry sponsored RCTs. This represents a remarkable amount of investment from researchers and healthcare systems to answer an important clinical question. We are unaware of other examples with such a large number of head‐to‐head non‐industry sponsored RCTs. </p> </li> <li> <p>RCTs were conducted across several countries: Austria, France, Germany, India, the Netherlands, Norway, UK, and the USA. </p> </li> <li> <p>The intervention implemented in these RCTs reflects the doses and regimens that are used in other countries. </p> </li> <li> <p>The included participants represent a wide spectrum of risks for cardiovascular diseases.</p> </li> </ol> </p> <p>This review provides evidence that is complete, comprehensive, and applicable to practice.</p> </section> <section id="CD011230-sec-0064"> <h3 class="title" id="CD011230-sec-0064">Quality of the evidence</h3> <p>We graded the overall quality of evidence as moderate for the majority of outcomes. Most published RCTs were thoroughly planned and well‐executed investigations that reported evidence on adverse events. Allocation concealment, masking, and attrition did not raise major concerns. We could not evaluate the quality for two unpublished studies. Reasons to rate down the overall quality of evidence included large confidence intervals for all safety outcomes (i.e., imprecision) and the sensitivity of the SSAE meta‐analysis to a few studies. </p> <p>The quality of evidence should be reassessed once the <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a> and <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a> trials are fully published. </p> </section> <section id="CD011230-sec-0065"> <h3 class="title" id="CD011230-sec-0065">Potential biases in the review process</h3> <p>Several important limitations should be noted, mainly due to the rapid timeline of the review. We obtained limited information from study authors, and several studies still had items of unclear risk of bias. The uncertain role of missing data, which is typically reported only in relation to efficacy, but not for safety, may have influenced the overall analyses; the direction of the bias is unpredictable, but we believe that the likelihood of this bias is minimal. The analysis of SSAEs was sensitive to the exclusion of data from an unpublished study, <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>. For this study, we derived SSAEs as a sum of all single SSAEs listed, assuming that one SSAE occurred in each participant. We assessed the quality of the evidence based solely on the adverse event profile related to the two drugs (i.e., we did not evaluate the comparative effectiveness of the drugs). A final limitation is that we did not include: i) outcomes such as blood pressure or left ventricular ejection fraction, which are signs that can lead to cardiovascular diseases, or ii) observational comparative studies (<a href="./references#CD011230-bbs2-0015" title="CampbellRJ , GillSS , BronskillSE , PatersonJM , WhiteheadM , BellCM . Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case‐control study. BMJ2012;345:e4203. ">Campbell 2012</a>; <a href="./references#CD011230-bbs2-0021" title="CurtisLH , HammillBG , SchulmanKA , CousinsSW . Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age‐related macular degeneration. Archives of Ophthalmology2010;128(10):1273‐9. ">Curtis 2010</a>; <a href="./references#CD011230-bbs2-0026" title="FrenchDD , MargoCE . Age‐related macular degeneration, anti‐vascular endothelial growth factor agents, and short‐term mortality: a postmarketing medication safety and surveillance study. Retina2011;31(6):1036‐42. ">French 2011</a>), since this would have required a different review methodology. </p> <p>Strengths of this review include the extensive search for published and unpublished studies; a multi‐disciplinary team; an in‐depth assessment of key findings in light of single studies as well the overall evidence; a standard methodology for conducting the review; and an a priori definition of the variables to include in the primary outcome SSAEs. </p> </section> <section id="CD011230-sec-0066"> <h3 class="title" id="CD011230-sec-0066">Agreements and disagreements with other studies or reviews</h3> <p>Our safety results differed from those of a parallel efficacy review (<a href="./references#CD011230-bbs2-0061" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3] ">Solomon 2014</a>, update under peer review), which showed an increased risk of adverse events for bevacizumab compared to ranibizumab (RR 1.27; 95% CI 1.06 to 1.52). Our systematic review included only head‐to‐head RCTs (the ones that directly compare bevacizumab and ranibizumab), while <a href="./references#CD011230-bbs2-0061" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3] ">Solomon 2014</a> included head‐to‐head as well standard treatment, placebo, or sham‐controlled RCTs. However, we included three additional RCTs (<a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>; <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>; <a href="./references#CD011230-bbs2-0009" title="NCT00559715 . Prevention of vision loss in patients with age‐related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting. clinicaltrials.gov/show/NCT00559715 (accessed 15 August 2014). ">VIBERA</a>) compared with the <a href="./references#CD011230-bbs2-0061" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3] ">Solomon 2014</a> update, considering both published and unpublished data. Furthermore, we provide a comprehensive assessment of the contribution of each RCT to the meta‐analyses, a 'Risk of bias' assessment that specifically targets risks related to adverse events, and several analyses to test the robustness of the overall estimates. </p> <p>Several previous reviews have assessed the safety of antiangiogenic therapy in people with neovascular AMD. Among these, <a href="./references#CD011230-bbs2-0020" title="CruessAF , GiacomantonioN . Cardiac issues of noncardiac drugs: the rising story of avastin in age‐related macular degeneration. Ophthalmologica2014;231(2):75‐9. ">Cruess 2014</a> recently reviewed different types of evidence on the safety of intravitreal bevacizumab in a non‐systematic fashion, including results from some RCTs and non‐randomised studies, studies on systemic vascular endothelial growth factor (VEGF) levels after intravitreal injections, and differences in molecular structure of bevacizumab and ranibizumab. However, bevacizumab was not directly compared with ranibizumab. <a href="./references#CD011230-bbs2-0016" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">Chakravarthy 2012</a> compared serum VEGF levels achieved with bevacizumab and ranibizumab: these were lower with bevacizumab, although the change in this biomarker has yet to be associated with adverse outcomes. <a href="./references#CD011230-bbs2-0017" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ">Chakravarthy 2013</a> pooled data from <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a> and <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> at two years and could not show a difference between bevacizumab and ranibizumab for deaths and arterial thrombotic events, but pointed out that SSAEs were higher with bevacizumab because of the enduring influence of the larger <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> study. In a recent systematic review and meta‐analysis, <a href="./references#CD011230-bbs2-0064" title="ThulliezM , AngoulvantD , LeLezML , Jonville‐BeraAP , PisellaPJ , GueyffierF , et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monocolonal antibodies: a systematic review and meta‐analysis. JAMA Ophthalmology 2014 July 24 [Epub ahead of print]. ">Thulliez 2014</a> showed no differences between bevacizumab and ranibizumab for the risk of major cardiovascular events or non‐ocular haemorrhagic events in people with neovascular AMD, but found significantly increased venous thromboembolic events for bevacizumab by cumulating data from three unspecified RCTs directly comparing bevacizumab with ranibizumab, totalling 15 events (12 in the bevacizumab arm versus three in the ranibizumab arm). We aggregated thromboembolic events with other serious adverse events previously associated with drugs affecting the VEGF pathway (e.g., arteriothrombotic events, vascular events, and death), totalling 150 events (79 in the bevacizumab arm versus 71 in the ranibizumab arm, <a href="./references#CD011230-fig-0014" title="">Analysis 1.11</a>), and did not find significant differences. A systematic review by Zhang et al analysed both evidence from observational and experimental studies, comparing bevacizumab with ranibizumab for efficacy and safety (<a href="./references#CD011230-bbs2-0069" title="ZhangXY , GuoXF , ZhangSD , HeJN , SunCY , ZouY , et al. Comparison of bevacizumab and ranibizumab in age‐related macular degeneration: a systematic review and meta‐analysis. International Journal of Ophthalmology2014;7(2):355‐64. ">Zhang 2014</a>). Again, the authors found only four RCTs (<a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>; <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a>; <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>), interpreted the unadjusted evidence from observational studies as compelling and free of bias, and overstated the strength of causal inference in the conclusions. Finally, another systematic review showed an increased risk of SSAEs in RCTs on several biologics for any indication (<a href="./references#CD011230-bbs2-0060" title="SinghJA , ChristensenR , WellsGA , Suarez‐AlmazorME , BuchbinderR , Lopez‐OlivoMA , et al. A network meta‐analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ2009;181(11):787‐96. ">Singh 2009</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011230-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for screened, included, and excluded study reports" data-id="CD011230-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for screened, included, and excluded study reports</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011230-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Bevacizumab versus ranibizumab, primary analysis at longest follow‐up, outcome: 1.1 All‐cause death." data-id="CD011230-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bevacizumab versus ranibizumab, primary analysis at longest follow‐up, outcome: 1.1 All‐cause death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Bevacizumab versus ranibizumab, longest follow‐up, outcome: 1.2 All serious systemic adverse events." data-id="CD011230-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Bevacizumab versus ranibizumab, longest follow‐up, outcome: 1.2 All serious systemic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 1 All‐cause death." data-id="CD011230-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 1 All‐cause death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 2 All serious systemic adverse events." data-id="CD011230-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 2 All serious systemic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 3 Arterial thromboembolic event." data-id="CD011230-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 3 Arterial thromboembolic event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 4 Gastrointestinal perforation." data-id="CD011230-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 4 Gastrointestinal perforation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 5 Infection." data-id="CD011230-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 5 Infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 6 Myocardial infarction." data-id="CD011230-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 6 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 7 Neutropenia." data-id="CD011230-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 7 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 8 Non‐ocular haemorrhage." data-id="CD011230-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 8 Non‐ocular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 9 Stroke." data-id="CD011230-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 9 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 11 Vascular events associated with anti‐VEGF treatment." data-id="CD011230-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 11 Vascular events associated with anti‐VEGF treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 12 Cardiac disorders MedDRA Class." data-id="CD011230-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 12 Cardiac disorders MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 13 Gastrointestinal disorders MedDRA Class." data-id="CD011230-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 13 Gastrointestinal disorders MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 14 General disorders and administration site conditions MedDRA Class." data-id="CD011230-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 14 General disorders and administration site conditions MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 15 Neoplasms benign, malignant, and unspecified MedDRA Class." data-id="CD011230-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 15 Neoplasms benign, malignant, and unspecified MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 16 Nervous system disorders MedDRA Class." data-id="CD011230-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 16 Nervous system disorders MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 17 Respiratory, thoracic, and mediastinal disorders MedDRA Class." data-id="CD011230-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Bevacizumab versus ranibizumab, longest follow‐up, Outcome 17 Respiratory, thoracic, and mediastinal disorders MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, one‐year of follow‐up, primary outcomes, Outcome 1 All‐cause death." data-id="CD011230-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, one‐year of follow‐up, primary outcomes, Outcome 1 All‐cause death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, one‐year of follow‐up, primary outcomes, Outcome 2 All serious systemic adverse events." data-id="CD011230-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, one‐year of follow‐up, primary outcomes, Outcome 2 All serious systemic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding CATT, Outcome 1 All serious systemic adverse events." data-id="CD011230-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding CATT, Outcome 1 All serious systemic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding LUCAS, Outcome 1 All serious systemic adverse events." data-id="CD011230-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding LUCAS, Outcome 1 All serious systemic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished studies, Outcome 1 All‐cause death." data-id="CD011230-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished studies, Outcome 1 All‐cause death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished studies, Outcome 2 All serious systemic adverse events." data-id="CD011230-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished studies, Outcome 2 All serious systemic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 1 All‐cause death." data-id="CD011230-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 1 All‐cause death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 2 All serious systemic adverse events." data-id="CD011230-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 2 All serious systemic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 3 Arterial thromboembolic event." data-id="CD011230-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 3 Arterial thromboembolic event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 4 Gastrointestinal perforation." data-id="CD011230-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 4 Gastrointestinal perforation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 5 Infections." data-id="CD011230-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 5 Infections. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 6 Myocardial infarction." data-id="CD011230-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 6 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 7 Neutropenia." data-id="CD011230-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 7 Neutropenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 8 Non‐ocular haemorrhage." data-id="CD011230-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 8 Non‐ocular haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 9 Stroke." data-id="CD011230-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 9 Stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 11 Vascular events associated with anti‐VEGF treatment." data-id="CD011230-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 11 Vascular events associated with anti‐VEGF treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 12 Cardiac disorders MedDRA Class." data-id="CD011230-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 12 Cardiac disorders MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 13 Gastrointestinal disorders MedDRA Class." data-id="CD011230-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 13 Gastrointestinal disorders MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 14 General disorders and administration site conditions MedDRA Class." data-id="CD011230-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 14 General disorders and administration site conditions MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 15 Neoplasms benign, malignant, and unspecified MedDRA Class." data-id="CD011230-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 15 Neoplasms benign, malignant, and unspecified MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 16 Nervous system disorders MedDRA Class." data-id="CD011230-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 16 Nervous system disorders MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011230-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/urn:x-wiley:14651858:media:CD011230:CD011230-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_t/tCD011230-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 17 Respiratory, thoracic, and mediastinal disorders MedDRA Class." data-id="CD011230-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses, Outcome 17 Respiratory, thoracic, and mediastinal disorders MedDRA Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/media/CDSR/CD011230/image_n/nCD011230-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011230-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bevacizumab compared with ranibizumab for neovascular age‐related macular degeneration</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with neovascular age‐related macular degeneration </p> <p><b>Intervention:</b> bevacizumab </p> <p><b>Comparison:</b> ranibizumab </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b> </p> <p>Follow‐up: 1 to 2 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> <br/> (27 to 53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b> (0.78 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3338<br/> (8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious systemic adverse events</b> </p> <p>Follow‐up: 1 to 2 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> <br/> (200 to 291) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> (0.90 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3665<br/> (9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> 1,2,3,4 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infection</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (36 to 69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.34</b> (0.97 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arterial thromboembolic event</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> <br/> (21 to 47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> (0.62 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Myocardial infarction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> <br/> (6 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> (0.42 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> <br/> (5 to 19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> (0.42 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,2,3 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal disorders MedDRA class</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> <br/> (16 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.82</b> <br/> (1.04 to 3.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> 1,4,5 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>For all outcomes, we judged the impact of missing data to be unclear: even the low rate of efficacy missing data, which was in the range of 5% to 10% for most studies, could have impacted on rare adverse events differences. However, we considered that a number of studies used an active monitoring for almost all participants across both arms, reducing the chance of missing SSAEs. We did not decrease the overall quality for risk of bias. </p> <p><sup>2</sup>People at high cardiovascular risk were excluded in <a href="./references#CD011230-bbs2-0001" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, <a href="./references#CD011230-bbs2-0007" title="KrebsI , SchmettererL , BoltzA , ToldR , Vecsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA</a>, and <a href="./references#CD011230-bbs2-0008" title="SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. ">Subramanian 2010</a>. <a href="./references#CD011230-bbs2-0002" title="SchauwvliegheA‐SM , DijkmanG , HooymansJM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. BRAMD. Investigative Ophthalmology and Visual Science2014;55:ARVO E‐Abstract 870. ">BRAMD</a>, <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a>, <a href="./references#CD011230-bbs2-0004" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL</a>, and <a href="./references#CD011230-bbs2-0005" title="ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , et al. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. ">IVAN</a> did not report exclusion criteria based on cardiovascular risks, and we considered them to represent a wide spectrum of risks as well as routine practice in secondary care settings. However, it is unclear as to how the results can be applied to high‐risk patients requiring long‐term treatment. We did not decrease the overall quality for indirectness. </p> <p><sup>3</sup>Wide 95% confidence interval considering relative risk and/or absolute events. We did decrease the overall quality for imprecision (‐1). </p> <p><sup>4</sup>The meta‐analytic estimate was sensitive to the exclusion of <a href="./references#CD011230-bbs2-0003" title="MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. ">CATT</a> and <a href="./references#CD011230-bbs2-0006" title="BergK . Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day. conference‐cast.com/AAO/common/sessions.aspx/4/7 (accessed 30 April 2014). ">LUCAS</a>, as well as two unpublished studies. We did decrease the overall quality for inconsistency (‐1). </p> <p><sup>5</sup>'Summary of findings' table outcome not pre‐specified in the review protocol. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/full#CD011230-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011230-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bevacizumab versus ranibizumab, longest follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.78, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All serious systemic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Arterial thromboembolic event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.62, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Gastrointestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.97, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.42, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Non‐ocular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.08, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.42, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Treatment‐related drug discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Vascular events associated with anti‐VEGF treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.52, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Cardiac disorders MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.89, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Gastrointestinal disorders MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.04, 3.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 General disorders and administration site conditions MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.32, 11.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Neoplasms benign, malignant, and unspecified MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Nervous system disorders MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.77, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Respiratory, thoracic, and mediastinal disorders MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.42, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bevacizumab versus ranibizumab, longest follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011230-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bevacizumab versus ranibizumab, one‐year of follow‐up, primary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.72, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All serious systemic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.90, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bevacizumab versus ranibizumab, one‐year of follow‐up, primary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011230-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding CATT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All serious systemic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding CATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011230-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding LUCAS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All serious systemic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.06, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Bevacizumab versus ranibizumab, influence analysis: all SSAEs excluding LUCAS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011230-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.78, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All serious systemic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.06, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Bevacizumab versus ranibizumab, influence analysis: primary outcomes excluding unpublished studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011230-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.78, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All serious systemic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.00, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Arterial thromboembolic event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.62, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Gastrointestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.97, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.37, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Non‐ocular haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.08, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.42, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10 Treatment‐related drug discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Vascular events associated with anti‐VEGF treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.85, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Cardiac disorders MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.88, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Gastrointestinal disorders MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.20, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 General disorders and administration site conditions MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.73, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Neoplasms benign, malignant, and unspecified MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Nervous system disorders MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.79, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Respiratory, thoracic, and mediastinal disorders MedDRA Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.42, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bevacizumab versus ranibizumab, secondary analysis: fixed‐effect analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011230.pub2/references#CD011230-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011230.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011230-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011230-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011230-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD011230-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011230\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011230\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011230\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011230\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011230\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011230.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011230.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011230.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011230.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011230.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719191134"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011230.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719191138"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011230.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de2ba0f629368',t:'MTc0MDcxOTE5MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 